Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva oral contraceptive gets EU approval
Zoely, a monophasic combination of 2 steroid hormones – 17-beta estradiol and nomegestrol acetate, will be made available in a convenient 24 day active and 4 day placebo
Zoely, a monophasic combination of 2 steroid hormones – 17-beta estradiol and nomegestrol acetate, will be made available in a convenient 24 day active and 4 day placebo
The integrated content along with T SystemEV aids providers with extensive drug and clinical data to improve the accuracy and safety of patient care for adult and pediatric
Olmesartan medoxomil, a member of the angiotensin receptor blocker (ARB) class of antihypertensive medications, is indicated for the treatment of hypertension. The companies’ Mexican subsidiaries Daiichi Sankyo Mexico
Earlier, Perforomist (formoterol fumarate) Inhalation Solution 20mcg/2ml vial was under revaluation by Sepracor, now known as Sunovion Pharmaceuticals. According to Dey Pharma, the two intended reissued patents and
The increase in revenue is driven by higher prescription volume and price inflation on brand drugs, offset by the impact of the increase in generic utilization. Catalyst‘s net
The FDA reserves final approval of the product, however, until all exclusivity or patent challenges have been resolved, specifically the current patent litigation brought against Intelliject by King
The double-blind, randomized and controlled trial is expected to compare two dose levels of CF101 to placebo. The company anticipates to recruit around 300 patients at 17 centers.
Net income was $2.61bn, compared to $2.48bn for the same period in the prior year. For the six months ended 2011 revenues were $33.49bn, compared to $33.71bn for
Caprelsa is indicated as a treatment of symptomatic or progressive medullary thyroid cancer in patients suffering from unresectable (non-operable) locally advanced or metastatic disease. The FDA approval for
Markison will also be a member of the board of the newly created standalone company, following the completion of the acquisition of Nycomed A/S by Takeda Pharmaceuticals. Previously,